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Cells can undergo either cell-cycle arrest or apoptosis after 
genotoxic stress, based on p53 activity1–6. Here we show that 
cellular fate commitment depends on Axin forming distinct 
complexes with Pirh2, Tip60, HIPK2 and p53. In cells 
treated with sublethal doses of ultra-violet (UV) radiation 
or doxorubicin (Dox), Pirh2 abrogates Axin-induced p53 
phosphorylation at Ser 46 catalysed by HIPK2, by competing 
with HIPK2 for binding to Axin. However, on lethal treatment, 
Tip60 interacts with Axin and abrogates Pirh2–Axin binding, 
forming an Axin–Tip60–HIPK2–p53 complex that allows 
maximal p53 activation to trigger apoptosis. We also provide 
evidence that the ATM/ATR pathway mediates the Axin–Tip60 
complex assembly. An axin mutation promotes carcinogenesis 
in AxinFu/+ (Axin-Fused) mice, consistent with a dominant-
negative role for AxinFu in p53 activation. Thus, Axin is a 
critical determinant in p53-dependent tumour suppression 
in which Pirh2 and Tip60 have different roles in triggering 
cell-cycle arrest or apoptosis depending on the severity of 
genotoxic stress.
Cells can limit the effects of genotoxin-induced DNA damage either 
by initiating apoptosis or by undergoing cell-cycle arrest to activate 
DNA repair. The molecular mechanisms underlying this fate decision 
remain obscure. The outstanding question has thus concerned the 
manner in which p53 activity is controlled such that cells regulate 
their reactions according to the severity of damage. A recent major 
advance in our understanding of the regulation of p53 functions has 
come from studies on HIPK2 (homeodomain-interacting protein 
kinase 2), which interacts with, and phosphorylates, p53 at Ser 46. 
This phosphorylation has been shown to be a critical determinant 
for cellular commitment to either cell-cycle arrest or apoptosis in 
response to different doses of genotoxic stress, including UV and 
Dox7–11. Interestingly, on treatment with Dox at a sublethal dose that 
causes cell-cycle arrest but not apoptosis, HIPK2 is degraded through 
ubiquitylation by MDM2 (ref. 9).
Axin was initially identified as a negative regulator of Wnt signalling 
and its mutation leads to duplication of the axis12,13. It has emerged as a 
major scaffold for many other signalling pathways, including mTOR14, 
JNK MAPK15, parathyroid hormone16 as well as for p53 signalling17,18. We 
have shown previously that Axin interacts with p53 in two ways, directly 
through the p53 middle (MID) domain and indirectly through HIPK2 
at the p53 carboxyl terminus17. Axin functions in UV-induced cell death 
by activating p53 by phosphorylating it at Ser 46, which is catalysed by 
HIPK2 (ref. 18), suggesting that Axin might exert a physiological role in 
genotoxic responses. The AxinFu allele is generated by insertion of an intra-
cisternal A-particle (IAP) at intron 6 (ref. 13); the large insertion blocks 
splicing of wild-type Axin. Thus, two Axin protein species are generated 
from the AxinFu allele, a C-terminal truncated protein designated AxinFu–NT 
(amino-acids 1–596) and wild-type Axin19. To investigate the longstanding 
question of why genetically transmitted inbred 129P4/RrRk Fused mice 
do not show a higher incidence of tumours, we treated the mice with 
the DNA-damaging reagent DMBA (7,12-dimethylbenz-a-anthracene), 
as described previously20. At 12 weeks post-treatment, a drastic increase 
in the number of tumours in the skin of the AxinFu/+ heterozygous mice 
was observed compared with wild-type mice (P < 0.001; Fig. 1a, b). The 
tumours showed characteristic papilloma morphology (Supplementary 
Information, Fig. S1a). To explore the functional association between the 
AxinFu mutation and the p53 system, we tested p53 transcriptional activ-
ity using a luciferase reporter in the mouse skin fibroblasts of both +/+ 
and AxinFu/+ mice, and observed a significant reduction in p53 transac-
tivational activity in AxinFu/+ fibroblasts on lethal Dox treatment, com-
pared with that in +/+ cells, suggesting that the mutant cells are defective 
in p53 signalling (Fig. 1c). In addition, we found that AxinFu–NT exerts 
a dominant-negative effect on Axin-induced p53 phosphorylation at 
Ser 46 (Fig. 1d), p53 transactivation activity (Supplementary Information, 
Fig. S1b) and on the induction of apoptosis (Fig. 1e), in H1299 cells. 
Mechanistically, AxinFu–NT retains the ability to bind to p53, but lacks a 
HIPK2-binding domain (located in the C terminus of wild-type Axin), 
therefore it lacks the ability to phosphorylate p53 (Fig. 1d; Supplementary 
Information, Fig. S1c). Consistently, AxinFu–NTΔMID, a mutant that lacks 
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the direct p53-binding (MID) domain, failed to show such a dominant-
negative effect on Axin-induced p53 Ser 46 phosphorylation (Fig. 1d). 
Moreover, AxinFu–NT can form heterodimers with wild-type Axin when 
co-expressed (Supplementary Information, Fig. S1d). These results indi-
cate that Axin may exert a critical role in preventing tumour formation 
induced by DNA damage. Apoptosis assays in Axin-null SNU-475 cells 
or U2OS cells depleted of Axin by siRNA further confirmed that Axin 
is required for the induction of apoptosis in response to Dox and UV 
treatment (Supplementary Information, Fig. S1e, f). Furthermore, Axin 
stimulated the transcription and protein levels of the p53AIP1 gene, which 
is known to be induced by p53 phosphorylation on Ser 46 (Supplementary 
Information, Fig. S1g, h)13.
To gain further insights into how Axin controls p53 activation, we 
carried out a yeast two-hybrid screen using the PP2A-binding domain 
of Axin (amino-acids 501–712) as bait. One of the identified clones 
encoded Pirh2 (Supplementary Information, Fig. S2a). To confirm the 
interaction, we performed co-immunoprecipitation using endogenous 
proteins from U2OS cell lysates, and found that Axin was detected in the 
immunoprecipitate of Pirh2 (Fig. 2a). GST (glutathione S-transferase) 
pulldown experiments showed that GST–Pirh2, but not GST itself, can 
directly interact with His–Axin (Fig. 2b). To determine their interacting 
regions, we generated a series of deletion mutants of Axin and Pirh2 
(schematically outlined in Supplementary Information, Fig. S2b, c) and 
found that amino-acids 506–576 of Axin are necessary for interaction 
with amino-acids 211–240 of Pirh2. Two-step co-immunoprecipitation 
indicated that Axin, Pirh2 and p53 could co-exist in the same complex 
in vivo (Fig. 2c). In addition, Pirh2 interactions with Axin and p53 did 
not seem to interfere with each other, as Pirh2ΔAxin (a mutant lacking an 
Axin-binding domain) could interact with p53, and Pirh2Δp53 (a mutant 
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Figure 1 Mutation of Axin in AxinFu/+ mice promotes tumour formation. 
(a) Papillomas in wild-type and AxinFu/+ mice after 12 weeks of DMBA 
treatment. New born mice were treated with DMBA followed by TPA 
(12-O-tetra-decanoylphorbol-13-acetate) treatment twice a week.  
(b) The tumour numbers of DMBA-treated wild-type and AxinFu/+ mice 
were counted and subjected to statistical analysis using Student’s 
t-test. Data are mean ± s.e.m. from three independent experiments in 
duplicate. (c) Reduced p53 transactivation activity in AxinFu/+ mouse 
skin fibroblasts. Primary AxinFu/+ and +/+ mouse skin fibroblasts were 
generated and transfected with a p53 luciferase reporter. At 24 h post-
transfection, cells were left untreated or treated for 12 h with 2.5 μM Dox, 
before luciferase activity was measured. The results were normalized to 
LacZ activity and are mean ± s.e.m. from three separate experiments. (d) 
AxinFu–NT negatively regulates p53 Ser 46 phosphorylation induced by wild-
type Axin. H1299 cells were transfected with Axin, AxinFu–NT, AxinFu–NTΔMID 
and Myc–p53 in combinations as indicated. At 30 h post-transfection, 
p53 was immunoprecipitated before western blotting to detect p53 Ser 
46 phosphorylation. IP, immunoprecipitation; IB, immunoblotting; TCL, 
total cell lysates. (e) Inhibition of Axin-induced, p53-dependent apoptosis 
by AxinFu–NT. H1299 cells were transfected with different combinations 
of plasmids as indicated. At 30 h post-transfection, apoptotic cells were 
counted. Data are mean ± s.e.m., n = 3.
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Information, Fig. S3a, b). For a first approximation, we used ectopically 
expressed proteins to determine the effect of Pirh2 on Axin-induced 
p53 Ser 46 phosphorylation. It was found that Pirh2 robustly abrogated 
p53 phosphorylation, p53 transactivational activity and the induc-
tion of apoptosis, which depends on the interaction of p53 with Axin 
(Supplementary Information, Fig. S3c–e). Pirh2 was unable to inhibit 
AxinΔPirh2-activated p53 Ser 46 phosphorylation or p53 transactivational 
activity (Supplementary Information, Fig. S3f, g). Knockdown of Pirh2 in 
Dox or UV treated U2OS cells led to an increase in p53 Ser 46 phosphor-
ylation (Fig. 2d), protein levels of p53AIP1 (Supplementary Information, 
Fig. S3h) and in the rate of apoptosis (Fig. 2e).
Pirh2 is characterized by its RING-H2 domain and has been 
shown to be an E3 ligase towards p53 (ref. 21). We thus assessed 
the importance of the E3 ligase activity of Pirh2 in its attenuation of 
Axin-induced p53 phosphorylation. Surprisingly, the Pirh2C145A and 
Pirh2C164A ligase-dead mutants21,22 retained the ability to inhibit Axin-
induced p53 phosphorylation without altering overall levels of p53 
(Fig. 3a). We then performed in vitro ubiquitylation assays to deter-
mine the E3 activity of Pirh2 towards p53 by using Mdm2 as a posi-
tive E3 control, using the protocol described previously21. GST–Pirh2 
did not show E3 activity towards p53, whereas Mdm2 strongly ubiq-
uitylated p53 (Supplementary Information, Fig. S4a). To investigate 
further, we included p27 as a positive control for Pirh2 E3 ligase activ-
ity23. Whereas Pirh2 did indeed show strong E3 activity towards p27 
(Supplementary Information, Fig. S4b), it did not show any ubiquit-
ylating activity towards p53. The indistinguishable inhibitory effects 
of wild-type Pirh2 and its Pirh2C145A mutant on p53 activation were 
recapitulated in a xenograft tumour growth assay using nude mice 
(Fig. 3b; Supplementary Information, Fig. S4c, d). In addition, Pirh2 
could no longer promote the tumour growth of p53-depleted cells, 
indicating that Pirh2 stimulates xenograft tumour growth by inhibiting 
p53 function (Fig. 3b, bottom).
The observation that Pirh2 attenuates Axin-induced p53 Ser 46 phos-
phorylation independently of its E3 activity prompted us to explore 
the possibility that Pirh2 might block HIPK2 binding to Axin. Indeed, 
Pirh2 could compete against HIPK2 for binding to Axin (Supplementary 
Information, Fig. S4e). We also performed an in vitro reconstitution assay, 
and found that increasing amounts of Pirh2 dissociated HIPK2 from Axin 
(Supplementary Information, Fig. S4f). Consistently, knockdown of Pirh2 














































































































Figure 2 Pirh2 interacts with Axin and inhibits Axin-induced p53 activation 
and apoptosis. (a) U2OS cell lysates were subjected to immunoprecipitation 
with control IgG or a rabbit anti-Pirh2 polyclonal antibody against endogenous 
Pirh2. The immunoprecipitates along with total cell lysates were analysed by 
western blotting with anti-Pirh2 or anti-Axin antibodies. Mock, without lysate. 
(b) Direct interaction between Pirh2 and Axin was determined by a pulldown 
assay. GST pulldown was performed with His–Axin (2 μg) and GST–Pirh2 
(2 μg) or GST as a control. (c) Axin, Pirh2 and p53 form a ternary complex. 
Two-step co-immunoprecipitation was performed using U2OS cell lysates as 
outlined on the left. It was initally performed using anti-Axin (C2b), followed 
by elution with the polypeptide against which the C2b antibody was raised 
(C2b polypeptide). The eluates were subjected to immunoprecipitation with 
anti-p53 (DO-1) or control IgG before immunoblotting to detect Axin, Pirh2 
and p53. (d) UV-induced p53 Ser 46 phosphorylation (p-p53 Ser 46) was 
decreased by knockdown of Axin, but increased by knockdown of Pirh2. 
U2OS cells were transfected with pSUPER-Axin, pSUPER-Pirh2 or control 
siRNA expression vectors. At 30 h post-transfection, cells were irradiated 
with 80 J m–2 UV and collected for immunoprecipitation with DO-1 at 8 h 
after irradiation. The immunoprecipitates were analysed for total p53 and 
phosphorylated p53. Total cell lysates were analysed for Axin, Pirh2, p53 and 
β-actin. (e) Knockdown of Pirh2 increases the rate of apoptosis induced by 
genotoxic treatment. pSUPER-Pirh2-3- or control siRNA-transfected U2OS 
cells were treated with Dox (2.5 μM; left) or UV (80 J m–2; right) 24 h post 
transfection. An additional 24 h later, apoptotic cells were counted after 
Hoechst staining. Data are mean ± s.e.m., n = 3. IP, immunoprecipitation; 
IB, immunoblotting; TCL, total cell lysates.
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(Fig. 3c). In parallel, as Tip60 has been implicated in the regulation of p53 
activity under genotoxic stress24–26, we tested whether Axin also interacted 
with Tip60 and found that Tip60 was readily detected in the immuno-
precipitate by an anti-Axin antibody (Fig. 4a). GST pulldown experi-
ments showed that Axin directly interacts with Tip60 (Fig. 4b). Two-step 
co-immunoprecipitation using endogenous proteins revealed that Tip60 
forms a ternary complex with Axin and p53 (Supplementary Information, 
Fig. S5a). Notably, the Pirh2-binding domain of Axin (amino-acids 507–
576) also interacts with Tip60 (amino-acids 259–389; Supplementary 
Information, Fig. S5b, c). We therefore tested whether Tip60 might affect 
Pirh2 binding to Axin. As shown in Fig. 4c, when Tip60 was co-expressed, 
Pirh2 co-precipitation with Axin was decreased, indicating that Tip60 
and Pirh2 are mutually exclusive in their binding to Axin. In addition, an 
acetyltransferase-dead form of Tip60 (mutant Q377E/G380E, Tip60ATD) 
excluded Pirh2 from Axin as efficiently as wild-type Tip60, indicating 
that it is unlikely that the enzymatic activity of Tip60 is involved in its 
competion with Pirh2 for Axin interaction. An in vitro reconstitution 
assay also confirmed the competitive binding between Tip60 and Pirh2 
to Axin (Supplementary Information, Fig. S5d).
The diversity of complexes centred on Axin led us to explore whether 
such distinct complexes are formed in cells in response to differing 
severities of genotoxic insults. We treated cells with varying doses of Dox 
(Supplementary Information, Fig. S6a, b); 0.4 μM and 2.5 μM were the 
doses required for U2OS cells to undergo cell-cycle arrest and apoptosis, 
respectively. We then carried out immunoprecipitation to analyse complex 
formation among endogenous Axin, Pirh2 and Tip60 after sublethal or 
lethal drug treatment. A higher level of Pirh2 was co-precipitated with Axin 
in cells treated with the sublethal dose of Dox than in lethal dose-treated 
cells. In contrast, a higher amount of Tip60 was co-precipitated with Axin in 
the lethal dose-treated cells, despite the relatively unchanged protein levels 
of Pirh2 and Tip60 (Fig. 4d). In the same experiment, it was also found 
that higher levels of p53 were associated with Axin than in untreated cells, 
irrespective of sublethal or lethal treatment (probably due to increased p53 
levels as a result of the Dox treatment) and that more HIPK2 was associated 
with Axin on lethal treatment, which is in accordance with the competitive 
nature of Pirh2 and HIPK2 in binding to Axin. Higher levels of Tip60 and 
lower levels of Pirh2 associated with Axin were also seen in cells treated 
with a lethal dose of UV (80 J m–2) than in cells treated with a sublethal dose 
(10 J m–2; Supplementary Information, Fig. S6c). Furthermore, in lethally 
treated cells depleted of Tip60 by siRNA, levels of Pirh2 co-precipitated 
with Axin were as high as those in sublethally treated cells, highlighting 
the importance of the competitive nature of Tip60 and Pirh2 binding in 
cells that are exposed to lethal radiation (Fig. 4e). To observe the dynamic 
interactions among Axin, p53, Pirh2 and Tip60 at their endogenous lev-
els in vivo, we performed a series of immunostaining experiments. Axin 
interaction with p53 in the nucleus was increased under UV lethal treat-
ment, concomitant with an increase in levels of nuclear Axin and p53 
(Supplementary Information, Fig. S7). Axin interacts with Pirh2 in both 
b
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Figure 3 Pirh2 inhibits Axin-induced p53 activation independently of its E3 
ligase activity. (a) Pirh2 and its ligase-dead mutants, Pirh2C145A and Pirh2C164A, 
effectively inhibit p53 Ser 46 phosphorylation. H1299 cells were cotransfected 
with the indicated combinations of HA-Axin, Pirh2, Pirh2C145A, Pirh2C164A and 
Myc–p53, before p53 Ser 46 phosphorylation levels were determined. Pirh2C145A 
and Pirh2C164A inhibited Axin-induced p53 Ser 46 phosphorylation as effectively 
as wild-type Pirh2. (b) Top, Pirh2C145A promotes xenograft tumour growth in nude 
mice as effectively as wild-type Pirh2. Data are mean ± s.e.m., n = 3, Student’s 
t-test. Bottom, Pirh2 promotes tumour growth by suppressing p53 function. 
The endogenous p53 in U2OS cells was knocked down by siRNA, and growth 
of the cells was not affected by Pirh2. Data are mean ± s.e.m., n = 3, Student’s 
t-test. (c) Knockdown of Pirh2 by pSUPER-Pirh2-2 or pSUPER-Pirh2-3 results 
in higher levels of HIPK2 co-immunoprecipitated with Axin. U2OS cells were 
transfected with pSUPER-Pirh2-2, pSUPER-Pirh2-3 or control siRNA and 
their cell lysates were subjected to immunprecipitation with a rabbit anti-Axin 
antibody (C2b, for endogenous Axin) or IgG as a control. Immunoprecipitates 
were analysed for Axin, HIPK2, Pirh2 and p53. IP, immunoprecipitation; IB, 
immunoblotting; TCL, total cell lysates.
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the nucleus and cytoplasm of untreated and sublethally treated cells, but 
their co-staining was decreased in lethally treated cells (Supplementary 
Information, Fig. S8). Tip60 colocalized to Axin in perinuclear cytoplasmic 
areas in untreated or sublethally treated cells, and in the nucleus after lethal 
treatment (Supplementary Information, Fig. S9). A triple co-staining exper-
iment confirmed that Axin, p53 and Tip60 are most prominently colocal-
ized in the nucleus in response to lethal UV treatment (Supplementary 
Information, Fig. S10).
We next determined the effects of Tip60 on Axin-induced p53 activity. 
Consistent with competitive binding of Tip60 against Pirh2 to Axin, Tip60 
could reverse the inhibition by Pirh2 of Axin-induced p53 activation, 
including phosphorylation at Ser 46 (Fig. 4f) and p53 transactivational 
activity (Supplementary Information, Fig. S11a). We further addressed 
the physiological roles of Tip60 in U2OS cells in response to sublethal or 
lethal treatment with Dox. Knockdown of Tip60 resulted in decreased p53 
Ser 46 phosphorylation on lethal Dox treatment (Fig. 4g). The ability of 
Tip60 to reverse the inhibitory effect of Pirh2 on Axin-induced growth 
inhibition was confirmed by a colony formation assay (Supplementary 
Information, Fig. S11b). We also found that Tip60 depletion reduced the 
number of cells undergoing apoptosis induced by lethal DNA damage 
(Supplementary Information, Fig. S11c). We further tested the effects of 
Axin, Pirh2 or Tip60 knockdown on cell-cycle progression, and found 
that it was not affected in untreated cells or cells sublethally treated with 
Dox, consistent with our previous assertion that Axin does not activate 
p53 transactivational activity on p21 (cyclin-dependent kinase inhibi-
tor 1A, which mediates the p53-dependent cell-cycle G1 phase arrest; 
Supplementary Information,  Fig. S11d, e) 17,18.
We attempted to delineate the signalling pathways that dictate dif-
ferent complex formation according to DNA damage severity, and 
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Figure 4 Tip60 interacts with Axin and reverses Pirh2 inhibition of p53.  
(a) U2OS cell lysates were subjected to immunoprecipitation with control 
IgG or an anti-Axin antibody (C2b), before western blotting with anti-Tip60 
(1-211) and anti-Axin antibodies. (b) Direct interaction between Tip60 and 
Axin determined by a pulldown assay. GST pulldown was performed with His–
Axin (2 μg) and  GST–Tip60 (2 μg) or GST as a control. (c) Tip60 and Tip60ATD 
(acetyltransferase dead), but not Tip60∆Axin (which lacks the Axin-binding 
domain), prevent Pirh2 from binding to Axin. Myc–Axin, Pirh2, HA–tagged 
Tip60, Tip60ΔAxin or Tip60ATD were co-transfected in different combinations 
as indicated. Myc–Axin was immunoprecipitated, before precipitates were 
analysed for Tip60 and Pirh2. Tip60∆Axin failed to dissociate Pirh2 from 
Axin. (d) Decreased Pirh2–Axin and increased Tip60–Axin interactions on 
treatment with a lethal dosage of Dox. U2OS cells were untreated or treated 
with Dox (0.4 μM or 2.5 μM) for 18 h, before immunoprecipitation with anti-
Axin (C2b). Immunoprecipitates and total cell lysates were analysed for Axin, 
Pirh2, Tip60, p53 or HIPK2. (e) Knockdown of Tip60 leads to increased 
amounts of Axin-associated Pirh2 on treatment with a lethal dosage of Dox. 
U2OS cells depleted of Tip60 were untreated or treated with Dox (0.4 μM 
or 2.5 μM) for 18 h, before immunoprecipitation with anti-Axin (C2b). 
Immunoprecipitates and total cell lysates were analysed for Axin, Pirh2 and 
Tip60. (f) Tip60 reverses Pirh2 attenuation of Axin-induced p53 activation. 
H1299 cells were transfected with HA–Axin, Tip60, Pirh2 and Myc-p53 in 
the combinations indicated. Cells were lysed and immunoprecipitated with 
an anti-Myc antibody at 24 h post-transfection, followed by analysis with 
the indicated antibodies. (g) Knockdown of Tip60 decreased the p53 Ser 46 
phosphorylation induced by treatment with a lethal dose of Dox. At 24 h 
after transfection with control siRNA or pSUPER-Tip60, U2OS cells were 
untreated or treated with Dox (0.4 μM or 2.5 μM) for 18 h. Cells were then 
lysed and subjected to western blotting with the indicated antibodies. IP, 
immunoprecipitation; IB, immunoblotting; TCL, total cell lysates.
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Figure 5 ATM, ATR and Chk1 are involved in Tip60-enriched p53 activating 
complex centred on Axin. (a) U2OS cells were pretreated with DMSO 
alone, DMSO containing an ATM and ATR inhibitor (inh; 5 μM) or DMSO 
containing an inhibitor for ATM only (10 μM) for 1 h before treatment with 
Dox (0.4 μM or 2.5 μM) for 18 h, followed by immunoprecipitation using an 
anti-Axin (C2b) antibody. Western blotting of the precipitates was performed 
with anti-Axin and anti-Tip60 (1-211) antibodies. (b) Knockdown of ATM 
and ATR abolishes the increase in Tip60–Axin interaction on treatment 
with a lethal dose of Dox. U2OS cells were infected with lentiviral pLL3.7-
control siRNA, pLL3.7-ATM or pLL3.7-ATR. Cells were left untreated or 
treated with Dox (0.4 μM or 2.5 μM) for 18 h, before immunoprecipitation 
with an anti-Axin (C2b) antibody. The immunoprecipitates and total cell 
lysates were analysed with the antibodies indicated. (c) Inhibition of Chk1 
abolished the increase in Tip60–Axin interaction in cells treated with a 
lethal dose of Dox. U2OS cells were pretreated with a Chk1 (5 μM) or Chk2 
(1 μM) inhibitor for 1 h before treatment with Dox (0.4 μM or 2.5 μM). 
At 18 h post-treatment, cell lysates were immunoprecipitated with an 
anti-Axin (C2b) antibody, followed by western blotting with anti-Axin and 
anti-Tip60 (1-211) antibodies. (d) Knockdown of Chk1 abolishes the 
increase in Tip60–Axin interaction. U2OS cells were infected with lentiviral 
control siRNA or pLL3.7-Chk1. Cells were left untreated or treated with 
Dox (0.4 μM or 2.5 μM) for 18 h, followed by immunoprecipitation using 
an anti-Axin antibody. The immunoprecipitates and total cell lysates were 
analysed with the antibodies indicated. (e) A simplified model shows that 
Axin coordinates the functions of HIPK2, Pirh2 and Tip60 to modulate 
the activity threshold of p53. The left shows that in normal or sublethally 
damaged cells the Axin–p53 complex is primarily occupied by Pirh2, 
such that the complex is devoid of the activating kinase HIPK2. However, 
on exposure to lethal damage (right), Tip60 is activated by ATM/ATR 
through Chk1 and subsequently binds to Axin, leading to dissociation 
of Pirh2 from Axin and allowing the formation of a complex consisting 
of Axin, HIPK2, p53 and Tip60 that leads to maximal activation of p53 
through phosphorylation at Ser 46, which ultimately triggers apoptosis. IP, 
immunoprecipitation; IB, immunoblotting; TCL, total cell lysates.
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Rad3-related; both DNA-damage sensors) are involved. In U2OS cells, 
although an inhibitor of ATM alone mildly reduced the level of Axin-
bound Tip60 under lethal Dox treatment, an inhibitor of both ATM and 
ATR caused a far greater decrease in Tip60 co-immunoprecipitated with 
Axin (Fig. 5a). Furthermore, knockdown of ATM or ATR dampened the 
increase of Axin–Tip60 interaction after lethal DNA damage (Fig. 5b). 
These results indicate that ATM and ATR kinases can impinge on the 
Axin–Tip60 complex formation, further linking Axin to the genoto-
xic response cascade. It should be noted that although ATM and ATR 
could also be activated on sublethal DNA damage, they did not alter 
Axin–Tip60 interaction, compared with untreated cells. A possible 
explanation is that the pro-apoptotic Axin–Tip60 complex formation 
may require higher kinase activity levels and/or that the kinases have 
different subcellular localizations or binding partners under differ-
ent conditions. As recent reports have shown, HIPK2 activity can be 
modulated by ATM and ATR27, we considered whether HIPK2 could 
modulate the affinity of Pirh2 and Tip60 for Axin. However, as shown 
in Supplementary Information, Fig. S11f, HIPK2 knockdown had no 
impact on Tip60–Axin interaction. To investigate further, we tested 
whether Chk1 and Chk2 (cell-cycle checkpoint kinases 1 and 2, ATM 
and ATR substrates) are involved in the regulation of Axin–Tip60 inter-
action on lethal DNA treatment. We found that Chk1, but not Chk2, is 
necessary to elevate Axin–Tip60 interaction (Fig. 5c, d), emphasizing the 
link between the ATM and ATR signalling cascade and Axin-mediated 
apoptosis in response to lethal DNA damage.
This study reports two interacting partners for Axin, Pirh2 and Tip60, 
and a new Axin-centred regulatory circuitry for fine-tuning the p53 
activition threshold in response to differing severities of genotoxic stress. 
In non-severely damaged cells, Pirh2 interacts with Axin and causes 
dissociation of HIPK2 from Axin (Fig. 5e), suggesting that in these cells 
HIPK2 does not participate in p53 Ser 46 phosphorylation. In fact, our 
study is consistent with the finding that in non-severely damaged cells, 
HIPK2 is degraded by Mdm2 (ref. 9). Under lethal doses of genoto-
xic stress, ATM and ATR activate Tip60, enabling it to interact with 
the Axin–HIPK2–p53 activation complex by excluding the inhibiting 
Pirh2 to elicit an irreversible apoptotic process that eliminates severely 
damaged cells.  This unifies the critical roles of HIPK2 and Tip60 in 
the induction of apoptosis on lethal DNA damage. A carcinogenesis-
induction experiment using the AxinFu/+ mouse cell line has uncovered 
that Axin is a latent tumour suppressor; we further suggest that Axin 
may be prototypic of a great number of latent regulatory factors whose 
deletion or truncation mutants do not show apparent phenotypes in mice 
unless triggered by genotoxins or other stress signals. 
METHODS
Methods and any associated references are available in the online version 
of the paper at http://www.nature.com/naturecellbiology/.
Note: Supplementary Information is available on the Nature Cell Biology website.
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METHODS
Plasmid constructions. Full-length cDNA encoding mouse Pirh2 was obtained 
by PCR using mouse testis cDNA. Point mutations of Pirh2 were generated by a 
PCR-based site-directed mutagenesis method using Pfu polymerase (Stratagene). 
Full-length cDNA encoding human Tip60 was obtained from an EST clone 
(IMAGE No. 601205534, Invitrogen). All expression plasmids were constructed 
in the pCMV5 vector. PCR products were verified by sequencing (Invitrogen). 
The details of the primer sequences used for point mutations and deletion muta-
tions are available on request. The various constructs of Axin, HIPK2 and p53 
were as described previously15.
RNA interference. The mammalian expression vector pSUPER or lentiviral based 
vector pLL3.7 were used for expression of siRNA in U2OS cells. All pSUPER-
based interfering plasmids were constructed by inserting a 19-nucleotide sequence 
corresponding to a specific transcribed region of a target gene, as described pre-
viously28. The 19-nucleotide sequences of Pirh2 targeted by pSUPER-Pirh2-1, 
pSUPER-Pirh2-2 and pSUPER-Pirh2-3 are 5-CTAGATCGCTTTAAAGTGA-3, 
5-TGCCGCTTGTGTCATGATA-3 and 5-CAATGAAG ATCATCAACTA-3, 
respectively. The sequence targeting p53 in pSUPER-p53 is 5-GACTCCA 
GTGGTAATCTAC-3; sequences for pSUPER-Axin and pSUPER-HIPK2 are as 
described previously17. Control siRNA was expressed by the pSUPER vector carry-
ing a 19-nucleotide scrambled sequence (5-TCCTACAAATTCCACAGTT-3). 
The sequences of Tip60 targeted by pSUPER-Tip60 and by pLL3.7-Tip60 are 
5-CGTCTGGATGAATGGGTGA-3 and 5-GAACCAGGACAACGAAGAT-3, 
respectively. The 19-nucleotide sequence of Axin targeted by pLL3.7-Axin is 
5-GGAGAAGATCATCGGCAA-3; the sequences for ATM and ATR in pLL3.7 are 
5-GAAGGAAGCCAGAGTACAA-3 and 5-GGTCAGCTGTCTACTGTTA-3, 
respectively. The 19-nucleotide sequence of Chk1 targeted by pLL3.7-Chk1 was 
5-GCGTGCCGTAGACTGTCCA-3.
Antibodies and drugs. Rabbit polyclonal anti-Axin antibodies C2b and C8b 
were raised as described previously17. Mouse anti-HA (F-7), anti-Myc (9E10), 
anti-p53 (DO-1), anti-p53 (FL393), anti-Axin (S-20), anti-HIPK2 (C-15), anti-
Pirh2 (T-18), anti-Tip60 (N-17) and anti-Chk1 (G-4) antibodies were from Santa 
Cruz Biotechnology, Inc. The mouse anti-Flag (M2) antibody was from Sigma. The 
rabbit polyclonal phospho-p53Ser–46 antibody was from Cell Signaling Technology. 
The rabbit polyclonal anti-Pirh2 (CA1012) antibody was from Calbiochem. The 
Tip60 antibody was from Upstate (Cat. No. 07-038). The mouse polyclonal antibody 
against Tip60 (1-211) was generated by immunizing mice with a GST-fusion protein 
containing amino-acids 1–211 of human Tip60. The rabbit polyclonal antibody 
against Tip60 (M) was generated by immunizing rabbits with a GST-fusion protein 
containing amino-acids 149–250 of human Tip60. Antibodies against p53AIP1 
(ab3678) were from Abcam. Antibodies against ATM (Ab-3) and ATR (Ab-2) were 
from Calbiochem. Doxorubicin was from Sigma (Cat. No. D44583). The ATM/
ATR (Cat. No. 118501), ATM (Cat. No. 118500), Chk1/Wee1 (Cat. No. 681637) 
and Chk2 (Cat. No. 220485) inhibitors were from Calbiochem. Blasticidin was from 
InvivoGen (Cat. No. ant-bl-5b). All primary antibodies for immunoblotting were 
used at a 1:1,000 dilution, except for anti-Pirh2 (1:10,000) and anti-ATM (1:100).
Cell culture, transient transfection, immunopreciptation and western blotting. 
H1299 and U2OS cells were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 IU 
penicillin and 100 mg ml–1 streptomycin at 37°C in a humidified incubator con-
taining 5% CO2. Mouse skin fibroblasts were obtained from AxinFu/+ or +/+ mice 
by trypsin digestion of the mouse skin after mincing, and were cultured in DMEM 
with 10% fetal bovine serum, non-essential amino acids, sodium pyrovate, 2 mM 
L-glutamine, 100 IU penicillin and 100 mg ml–1 streptomycin. Lipofectamine 
2000 was used for transfection. Over 90% transfection efficiency was achieved in 
U2OS and H1299 cells. To ensure an equal amount of total DNA was transfected 
in each sample, a corresponding empty vector was used for adjustment of total 
DNA. Transfected cells were collected at 30 h after transfection using a lysis buffer 
and immunoprecipitation was carried out as described previously17.
Yeast two-hybrid screening. Yeast two-hybrid screening was carried out using 
MATCHMAKER GAL4 Two-Hybrid System 3 (Clontech) according to the 
manufacturer’s instructions as described previously15. The bait was the PP2A 
domain (amino-acids 501–712) of mouse Axin.
Transcription reporter assays. The pathDetect p53-Luc reporter that car-
ries p53-specific enhancer elements was from Stratagene. The pGL3-p53AIP1 
luciferase reporter was constructed as described previously11. H1299 cells were 
transiently transfected with p53-Luc reporter (0.5 μg) and a trace amount of 
p53 (10 ng) along with other plasmids in different combinations. Each sample 
was supplemented with pCMV5-LacZ (0.5 μg), which expresses β-galactosidase, 
for monitoring the transfection efficiency. Where necessary, the total amount 
of transfected DNA in each plate was adjusted to 4 μg with the empty vector 
pCMV5. At 24 h after transfection, cells were collected and luciferase activity 
was measured, and presented as described previously18. β-galactosidase activ-
ity was measured by a spectrophotometer and used for normalization of the 
luciferase activity data. The results are presented as mean. ± s.e.m. from at least 
three independent experiments.
Immunofluorescence staining. U2OS cells grown on 22-mm2 coverslips in six-
well plates were washed once with PBS and fixed with 4% formaldehyde in PBS 
for 10 min at room temperature. Cells were then rinsed with PBS, before being 
treated with PBS, 0.2% Triton X-100, 2 mg ml–1 BSA and 1 mM NaN3 on ice for 
10 min. The coverslips were then incubated with PBS, 0.02% Triton X-100, 3% 
BSA and 1 mM NaN3 for 30 min. Cells were then incubated with 2 μg ml
–1 anti-
Axin (S-20), anti-p53 (DO-1) anti-Pirh2 (CA1012) or anti-Tip60 (M) in blocking 
solution for 30 min. Next, cells were washed four times with PBS, 0.02% Triton 
X-100, 1.5% BSA and 1 mM NaN3; incubated with 20 μg ml
–1  of bovine anti-goat 
Texas red (Santa Cruz), goat anti-mouse FITC (Santa Cruz), bovine anti-rabbit 
FITC (Santa Cruz) or goat anti-rabbit Alexa Fluor 647 (Invitrogen) in blocking 
solution for 30 min. Cells were then washed four times with PBS, 0.02% Triton 
X-100, 1.5% BSA and 1 mM NaN3 before being incubated with DAPI (1 μg ml
–1) 
in washing solution for 2 min. Specimens were mounted in 90% glycerol and 
sealed with nail polish.
Two-step co-immunoprecipitation. Two-step co-immunoprecipitation was per-
formed essentially according to the procedures described previously29. Briefly, 
U2OS cells were lysed with LSLD buffer, sonicated and centrifuged. The super-
natant was subjected to immunoprecipitation by incubating with an anti-Axin 
antibody (C2b) bound to Protein A/G-agarose beads for 2 h at 4 °C. The beads 
were washed with lysis buffer containing NaCl (150 mM) three times, and the 
Axin-based protein complexes were eluted with lysis buffer (300 μl) contain-
ing NaCl (250 mM) and C2b antigen (100 μg ml–1) for 2 h at 4°C. The second 
immunoprecipitation was performed using eluate (150 μl) from the first immu-
noprecipitate and lysis buffer (350 μl) containing NaCl (150 mM) and an anti-
p53 antibody (1 μg; DO-1) or a control IgG. The immunoprecipitates were then 
anlysed with indicated antibodies.
Tumorigenesis assays. Inbred 129P4/RrRk AxinFu/+ mice (Jackson Lab.) were 
maintained and genotyped as described previously19. Littermates from hetero-
zygous parents were treated with 0.5% DMBA (50 μl) in acetone on the dorsal 
posterior surface on postnatal day 2. One week later, the mice were further treated 
with 6.25 μg of TPA in 100 μl acetone twice a week for a total of 12 weeks. Papilloma 
and normal skin sections from wild-type and AxinFu/+ mice were fixed in 10% 
PBS-buffered formaldehyde and stained with hematoxylin and eosin. Images were 
taken with an Olympus microscope at various magnifications.
Xenograft tumour assays. For tumour formation in nude mice, pcDNA6.0, which 
harbours a blasticidin-resistant gene, was included in each transfection. After trans-
fection, cells were selected with blasticidin (10 μg ml–1) and the resistant cells (5×106 
cells in 100 μl DMEM per injection) were injected subcutaneously into the flanks 
of nude mice. Six weeks later, tumours were removed and weighed.
28. Brummelkamp, T. R., Bernards, R. & Agami, R. A system for stable expression of short 
interfering RNAs in mammalian cells. Science 296, 550–553 (2002).
29. Harada, J. et al. Requirement of the co-repressor homeodomain-interacting protein 
kinase 2 for ski-mediated inhibition of bone morphogenetic protein-induced transcrip-
tional activation. J. Biol. Chem. 278, 38998–39005 (2003).
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Figure S1 The molecular mechanism underlying the increased tumorigenesis 
in the mutant mice. (a) Normal skin and tumor tissues from DMBA-treated 
wildtype and AxinFu/+ mice were fixed in 10% formalin overnight and 
sectioned at 7 µm followed by staining with hematoxylin and eosin. Shown 
are representative images taken at ×4, ×10 and ×40 amplifications with 
an Olympus microscope. (b) AxinFu-NT has a dominant negative effect 
on Axin-stimulated transcriptional activity of the p53-luciferase reporter 
gene. H1299 cells were co-transfected with Axin or AxinFu-NT together with 
p53-Luc and trace amount of p53. Luciferase activities were measured. 
The results were normalized to the activity of LacZ and are presented as 
means±s.e.m. of five separate experiments. (c) The AxinFu-NT protein does 
not bind to HIPK2. U2OS cells were co-transfected with HA-HIPK2 and 
Myc-Axin or AxinFu-NT and immunoprecipitation was carried out with anti-HA 
for HIPK2, followed by western blotting to detect Axin. (d) AxinFu-NT interacts 
with wildtype Axin. HA-tagged AxinFu-NT was cotransfected with Myc-tagged 
wildtype Axin into U2OS cells. Immunoprecipitation was performed using 
anti-HA antibody, followed by western blotting using anti-HA or anti-Myc. 
(e) Axin null SNU475 cells infected with pBOBI vector (as a control) or Axin 
were exposed to 2.5 µM Dox (doxorubicin). At 30 h post treatment, cells 
were fixed and stained with Hoechst, apoptotic cells were counted. Error 
bars, s.e.m.; n=3. Reintroduction of Axin in SNU-475 cells by pBOBI-Axin 
resulted in higher apoptotic rate in Dox treated cells. (f) pSUPER-Axin 
and control siRNA were separately transfected into U2OS cells. Cells were 
treated with 2.5 µM Dox (left) or 80 J/m2 UV (right) 24 h posttransfection. 
Apoptotic cells were counted after Hoechst 33342 staining. Error bars, 
s.e.m.; n=3. Knockdown of Axin decreased the number of cells undergoing 
apoptosis upon treatment. (g) U2OS cells were transfected with Axin or 
vector, together with p53AIP1-Luc. At 24 h post transfection, luciferase 
activities were measured and normalized to the activity of LacZ. Error bars, 
s.e.m.; n=5. (h) H1299 cells were transfected with Axin or vector together 
with 0.5 µg p53. 24 h posttransfection, IB (immunoblotting) was performed 
to detect the proteins as indicated.
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Figure S2 Pirh2 is a novel Axin-interacting protein (a) Yeast two-hybrid 
screen was performed by using the fragment of aa 501-712 of mouse Axin 
as bait, and one of the clones identified in the pACT fish vector, as previously 
described1 encodes aa 23-261 of Pirh2. (b) Identification of the interacting 
domain of Axin for Pirh2. HA-tagged Pirh2 was cotransfected into HEK293T 
cells separately with pCMV5-Myc blank vector (lane 1), pCMV5-Myc-Axin 
(lane 2) and a series of Myc-tagged Axin mutants (lanes 3 to 7, N1, C1, M1, 
M2 and M3 as depicted in the schematic diagrams on the top). Cell lysates 
were immunoprecipitated with anti-HA antibody. Immunoprecipitates and TCL 
(total cell lysates) were analyzed by western blotting with anti-HA for Pirh2 and 
anti-Myc for Axin. The results indicate that the region of aa 506-576 of Axin 
interacts with Pirh2. (c) Identification of the Pirh2 domain for Axin interaction. 
Myc-tagged Axin was cotransfected into HEK293T cells with pCMV5-HA blank 
vector (lane 1), pCMV5-HA-Pirh2 (lane 2) and a series of HA-tagged Pirh2 
deletion mutants. Cell lysates were immunoprecipitated with anti-Myc antibody. 
Immunoprecipitates and total cell lysates were analyzed by western blotting 
with anti-HA for Pirh2 and anti-Myc for Axin. This mapping result together with 
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Figure S3 Pirh2 inhibits p53 activity and apoptosis induced by Axin. (a) (b) 
Pirh2∆p53 binds to Axin with an indistinguishable affinity from that of Pirh2 
for Axin; Pirh2∆Axin can bind to p53 as efficiently as wildtype Pirh2. U2OS 
cells were transfected with Pirh2, Pirh2∆Axin or Pirh2∆p53 together with 
Axin or p53. Immunoprecipitations were carried out against Axin or p53, 
immunoprecipitates and total cell lysates were analyzed by western blotting 
with anti-HA for Pirh2 and anti-Myc for Axin or p53. (c) Pirh2 abrogates Axin-
induced p53 phosphorylation at Ser-46. Myc-p53 was co-transfected with Axin, 
Pirh2 or Pirh2∆Axin into H1299 cells. At 30 h posttransfection, Myc-p53 was 
immunoprecipitated followed by western blotting with anti-phospho-p53Ser-46 
to detect levels of phosphorylated p53Ser-46, and with anti-p53 (DO-1) to 
determine the total amount of p53 immunoprecipitated. Total cell lysates were 
analyzed for expression levels of Axin and Pirh2 by using anti-HA and Pirh2 
polyclonal antibody, respectively. Pirh2, but not Pirh2∆Axin, inhibits p53Ser-46 
phosphorylation activated by Axin, indicating that physical interaction with 
Axin is required for Pirh2 to abolish Axin-induced p53Ser-46 phosphorylation. 
(d) Pirh2 inhibition of Axin-stimulated p53 transactivational activity depends 
on its interaction with Axin. H1299 cells were transfected with the expression 
plasmids of HA-Axin, Pirh2 or Pirh2∆Axin alone or in different combinations 
as indicated, together with p53, p53-Luc reporter and pCMV5-LacZ. At 24 h 
posttransfection, luciferase activities were measured. Results are presented 
as means±s.e.m. of five independent experiments. (e) Effect of Pirh2 or 
Pirh2∆Axin on Axin-induced p53-dependent apoptosis in H1299 cells. The 
cells were transfected with the combinations of plasmids as indicated, together 
with or without trace amount (10 ng) of Myc-p53. At 30 h posttransfection, 
apoptotic cells were counted and apoptosis rates are presented as 
means±s.e.m. of three independent experiments. (f) Pirh2 cannot inhibit 
Axin∆Pirh2-stimulated p53 phosphorylation at Ser-46. To assess if Pirh2 could 
attenuate p53Ser46 phosphorylation stimulated by Axin∆Pirh2 that is defective 
in binding to Pirh2, increasing amounts of Pirh2 (1, 2, 4 µg, respectively) 
were co-transfected with Axin∆Pirh2 (2 µg), followed by IP for p53. The 
immunoprecipitates were probed with anti-phospho-p53Ser46 as described 
above. (g) Pirh2 inhibits Axin-stimulated but not Axin∆Pirh2 stimulated p53 
transcriptional activity. H1299 cells were transfected with expression plasmids 
of Axin, Axin∆Pirh2 and Pirh2 in combinations as indicated, together with 
p53, p53-Luc reporter and pCMV5-LacZ. At 24 h posttransfection, cells were 
harvested and measured for luciferase activities. Results from five independent 
experiments are presented as means±s.e.m. (h) Knockdown of Pirh2 increased 
p53AIP1 expression. U2OS cells were transfected with control siRNA, 
pSUPER-Pirh2-2 or pSUPER-Pirh2-3. 24 h posttransfection, cells were lysed 
and the total cell lysates were subjected to western blotting against phospho-
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Figure S4 E3 ligase activity of Pirh2 is dispensable in its inhibition of p53 
function. (a) Pirh2 did not exhibit any E3 ligase activity towards p53 in 
vitro. In vitro ubiquitination reactions containing different combinations of 
components were performed, using GST-p53 as substrate. The resultant 
samples were then subjected to western blotting using anti-His antibody 
to detect poly-ubiquitinated products. (b) Pirh2 exhibit E3 ligase activity 
towards p27 but not p53 in vitro. E1, E2, His-Ub and GST-Pirh2 together with 
GST-p53 or GST-p27 were incubated in ubiquitination buffer for 2 h. The 
reaction were stopped by adding 2 × SDS sample buffer and western blotting 
was performed with anti-His antibody. (c) Interaction with Axin, but not its 
E3 ligase activity, is required for Pirh2 to promote xenograft tumor growth. 
H1299 cells were transfected with trace amount (10ng) of p53 and 0.3 µg of 
pcDNA6.0 vector carrying blasticidin resistant gene, together with or without 
5 µg of Axin or Pirh2-C145A or Pirh2 ∆Axin. Some 24 h after transfection, 
cells were selected with 10 µg/ml of blasticidin for one week. The resistant 
cell were then collected and 5×10P6P cells were used for each injection. The 
left side of all of the nude mice was injected with cells expressing p53 alone 
as control; the right side of each mouse was injected with cells co-expressing 
p53 and Axin (Group 1), Pirh2 (Group 2), Pirh2-C145A (Group 3), or Pirh2-
∆Axin (Group 4). Each combination of injections was performed in triplicate. 
Six weeks later, tumors were removed for photo-taking, and determination 
of weight for statistical analysis. Representative whole mice are shown. It is 
evident that cells expressing p53 alone did not develop into tumor (left side 
of each mouse), whereas the cells co-expressing p53 and wildtype Pirh2 or 
Pirh2-C145A mutant grew into tumors of similar sizes. Of important note, 
Pirh2-∆Axin did not promote tumor growth. (d) Statistical analysis (Student’s 
t-test) of the tumor weights for comparison between p53/Pirh2-expressing 
cells and p53/Pirh2-C145A-expressing cells. The values are represented as 
mean±s.e.m. of three independent experiments in triplicates. (e) Pirh2∆Axin 
does not compete against HIPK2 for binding with the Axin-p53 complex. 
Myc-Axin and FLAG-p53 were cotransfected into H1299 cells with HA-
HIPK2, Pirh2 and Pirh2∆Axin in different combinations as indicated. Anti-HA 
antibody was used to immunoprecipitate HA-HIPK2 and western blotting was 
carried out to detect Axin, HIPK2, p53 and Pirh2 in the immunoprecipitates. 
Axin-p53 complex was excluded from interacting with HIPK2 in the presence 
of Pirh2, but not in the presence of Pirh2∆Axin. (f) Pirh2 competes against 
HIPK2 binding to Axin-p53 complex in vitro. HA-HIPK2 was transfected 
into H1299 cells and immunoprecipitated with anti-HA antibody, and 
then dissociated from beads by elution with HA peptide. The HA-HIPK2 
was then mixed in lysis buffer containing GST, GST-Pirh2, GST-Axin and 
GST-p53 in combination as indicated. After 3 h of incubation, GST-Axin 
was immunoprecipitated with anti-Axin antibody (C2b). The inputs and the 
immunoprecipitates were then subjected to western blotting with anti-GST, 
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Figure S5 Tip60 is a novel Axin-interacting protein. (a) Axin, Tip60 and 
p53 form a ternary complex assessed by two-step co-IP using U2OS cell 
lysates. (b) Identification of the Axin domain responsible for interacting 
with Tip60. HEK293T cells were transfected with HA-Tip60 and a series of 
Myc-tagged Axin deletion mutants as depicted in the diagrams. HA-Tip60 
was immunoprecipitated, and the precipitates and TCLs were then subjected 
to western blotting with anti-Myc and anti-HA antibodies. (c) Identification 
of the Tip60 domain responsible for interacting with Axin. Myc-tagged Axin 
was cotransfected into HEK293T cells with pCMV5-HA-Tip60 or a series 
of HA-tagged Tip60 mutants (lanes 2 to 7, depicted in schematic diagrams 
on the top). Cell lysates were immunoprecipitated with anti-Myc antibody. 
Immunoprecipitates and total cell lysates were analyzed by western blotting 
with anti-HA for Tip60 and anti-Myc for Axin. (d) Recapitulation of the 
competitive binding between Tip60 and Pirh2 to Axin in vitro. Reconstitution 
of purified GST-Axin, GST-Pirh2 with increasing amounts of Tip60 was 
performed. After 3 h of incubation, Axin was immunoprecipitated with 
anti-Axin antibody (C2b). The inputs and the immunoprecipitates were 
then subjected to western blotting with anti GST, anti-Tip60, anti-Axin and 
anti-Pirh2 antibodies as indicated. The result shows that Tip60 is able to 
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Figure S6 Determination of sublethal and lethal doses of Dox for U2OS 
cells. (a) Cells were treated with different doses of Dox (0.1 µM to 5.0 
µM), and after 8, 12, 24, or 36 h of incubation the cells were subjected 
to flow cytometry analysis. Shown here are representative graphs of cell 
cycle distribution of U2OS cells treated with 0.4 µM Dox and 2.5 µM Dox, 
respectively. (b) Statistical analysis of Dox treated cells in a for their cell 
cycle distribution. It was found that cells undergo cell cycle arrest under 0.4 
µM Dox treatment with cells enriched at G2/M phase, and apoptosis under 
2.5 µM Dox treatment with sub-G1 cells increased. The values are shown 
as mean±s.e.m. of three independent experiments. (c) Decreased levels of 
Pirh2 and increased levels of Tip60 are associated within Axin under lethal 
dose UV treatment. U2OS cells were exposed to 10 J/m2 or 80 J/m2 UV 
and kept in culture medium for 8 h. IP was then performed with anti-Axin 
antibody (C2b) to pull down Axin complexes in the cell lysates. Cell lysates 
and immunoprecipitates were then subjected to western blotting with anti-
Axin, anti-Tip60 (1-211) and anti-Pirh2 antibodies as indicated.
Figure S6
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Figure S7 Immunofluorescent staining of endogenous Axin and p53. 
U2OS cells were untreated or treated with 10 J/m2 or 80 J/m2 UV, and 
were subjected to immunostaining at 4 h post-treatment as described in 
Supplementary Methods. Mock IgG was used as control. Upon UV treatment, 
p53 levels and nuclearly localized Axin were increased; enhanced co-
localization of Axin and p53 was seen in lethally treated cells.
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Figure S8 Immunofluorescent staining of endogenous Axin and Pirh2. Experimental procedures are as described above. In untreated and sublethally treated cells, 





Pirh2 Axin Merge DAPI
-
Control IgG
© 2009 Macmillan Publishers Limited.  All rights reserved. 
 
s u p p l e m e n ta ry  i n f o r m at i o n
www.nature.com/naturecellbiology 9
Figure S9 Staining of endogenous Axin and Tip60 in U2OS cells. Note that in untreated and sublethally treated cells, Axin is colocalized with Tip60 mostly in 
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Figure S10 Triple costaining of endogenous Axin, p53 and Tip60 in U2OS cells. Note that in lethally treated cells, prominent colocalization signal (white 
color after merging) is detected in the nucleus.
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Figure S11 (a) Tip60 overcomes the inhibitory effect of Pirh2 on Axin-
stimulated p53 transactivational activity. H1299 cells were transfected 
with Axin, Pirh2 and Tip60 in different combinations as indicated, together 
with trace amount of p53, p53-Luc and LacZ. Luciferase activities were 
measured after 24 h of transfection and the values were normalized to 
LacZ activities. Results of three independent experiments are presented as 
means±s.e.m. (b) Tip60 reverses the inhibition of Pirh2 on Axin-induced 
cell death of U2OS cells determined by colony formation assay. U2OS 
cells were transfected with Axin, Pirh2 and Tip60 alone or in combination 
as indicated, together with 0.1 µg of pcDNA6.0. At 24 h posttransfection, 
blasticidin was added into medium to select for transfected cells. Cells 
were cultured for another 10 days and then stained with crystal violet. The 
average intensity of each plate was calculated by Totallab TL100 software. 
(c) Knockdown of Tip60 reduces apoptosis rates induced by lethal DNA 
damage. U2OS cells were infected with lentiviral pLL3.7 harboring control 
siRNA or siRNA against Tip60. Cells were treated with 2.5 µM Dox (left) or 
80 J/m2 UV (right). 24 h later, apoptotic cells were counted after Hoechst 
staining. Error bars, s.e.m.; n=3. (d) Depletion of Axin, Pirh2 or Tip60 has 
no significant effect on cell cycle progression or cell cycle arrest caused by 
sublethal DNA damage. U2OS cells were transfected with pSUPER-Pirh2 or 
control siRNA together with 0.3 µg of pcDNA6.0 vector carrying blasticidin 
resistant gene. Some 24 h after transfection, cells were selected with 10 
µg/ml of blasticidin for one week. Axin- and Tip60-depleted cells were 
generated by lentivirus mediated siRNA using pLL3.7-Axin and pLL3.7-
Tip60. After 24 h of incubation with 0.4 µM Dox, the cells were subjected 
to flow cytometry analysis. (e) Percentage of cells in each cell-cycle phase 
as assayed in d. (f) Knockdown of HIPK2 has no effect on Tip60-Axin 
interaction in cells lethally treated with Dox. U2OS cells were transfected 
with control siRNA or pSUPER-HIPK2. At 20 h posttransfection, cells were 
left untreated or treated with 0.4 µM or 2.5 µM Dox for 18 h. The cell lysates 
were immunoprecipitated by anti-Axin (C2b). The immunoprecipitates and 
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